Formulation of Solid Lipid Nanoparticles Loaded with Nociceptin/Orphanin FQ (N/OFQ) and Characterization in a Murine Model of Airway Hyperresponsiveness.
AHR
N/OFQ
SLNs
airway inflammation
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
29 Sep 2022
29 Sep 2022
Historique:
received:
14
09
2022
revised:
26
09
2022
accepted:
26
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Asthma is characterized by chronic inflammation and a variable degree of airway hyperresponsiveness (AHR). Our previous papers documented a role for Nociceptin/Orphanin FQ (N/OFQ) and its receptor N/OFQ peptide (NOP) in AHR. Therefore, the aim of this study was to improve the bioavailability of N/OFQ by developing solid lipid nanoparticles (SLNs). N/OFQ-loaded SLNs were prepared by the Quasi Emulsion Solvent Diffusion (QESD) technique and then characterized. Brown Norway rats were sensitized to ovalbumin (OVA) and treated with an intratracheal administration of saline solution or N/OFQ-SLN. Then, 24 h after the last challenge, functional histological and molecular evaluations were performed. SLNs showed a mean diameter of 233 ± 0.03 nm, a polydispersity index (PDI) value around 0.28 ± 0.02 and a drug release percentage of 84.3. The in vitro release of N/OFQ from SLNs showed that the release of the peptide starts already after two hours of incubation. Animals receiving N/OFQ-SLN showed a significative decrease in allergen-induced AHR compared to the control group. These results showed the positive effects of N/OFQ-SLNs on the inflammatory process and on the mechanical properties of the airways, suggesting that the innovative nanotechnological approach may be therapeutically beneficial for asthmatic patients.
Identifiants
pubmed: 36297323
pii: ph15101210
doi: 10.3390/ph15101210
pmc: PMC9609590
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Références
Pharmaceutics. 2021 Sep 13;13(9):
pubmed: 34575531
Br J Pharmacol. 2005 Mar;144(6):813-20
pubmed: 15685213
Bioorg Med Chem. 2014 Jul 15;22(14):3703-12
pubmed: 24878361
Chem Phys Lipids. 2014 Jul;181:56-61
pubmed: 24717692
Drug Deliv Transl Res. 2021 Jun;11(3):1218-1235
pubmed: 32946043
N Engl J Med. 2001 Feb 1;344(5):350-62
pubmed: 11172168
Nat Rev Drug Discov. 2008 Aug;7(8):694-710
pubmed: 18670432
J Transl Med. 2018 May 23;16(1):140
pubmed: 29792199
Int J Mol Sci. 2014 Mar 04;15(3):3904-25
pubmed: 24599081
Indian J Pharm Sci. 2009 Jul;71(4):349-58
pubmed: 20502539
Nanomaterials (Basel). 2020 Feb 08;10(2):
pubmed: 32046269
J Pept Sci. 2004 Nov;10(11):678-90
pubmed: 15568682
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
Peptides. 2011 Jan;32(1):173-87
pubmed: 20934475
Chem Biodivers. 2021 Jan;18(1):e2000871
pubmed: 33351271
J Nanobiotechnology. 2018 Sep 19;16(1):71
pubmed: 30231877
Bioorg Med Chem. 2007 Jul 1;15(13):4434-43
pubmed: 17490886
Eur J Pharmacol. 2017 Jan 5;794:115-126
pubmed: 27871910
Peptides. 2010 Jan;31(1):184-93
pubmed: 19819278
Br J Pharmacol. 2004 Mar;141(6):1077-83
pubmed: 14993101
Methods Mol Biol. 2020;2059:1-54
pubmed: 31435914
J Control Release. 2010 Jun 1;144(2):233-41
pubmed: 20153385
Pharmacol Rev. 2001 Sep;53(3):381-415
pubmed: 11546835
Mediators Inflamm. 2016;2016:3917471
pubmed: 28090152
Chem Phys Lipids. 2020 Nov;233:105003
pubmed: 33096096
Ophthalmic Physiol Opt. 2014 Sep;34(5):502-8
pubmed: 24697967
Int J Nanomedicine. 2012;7:3667-77
pubmed: 22888226
Br J Pharmacol. 2014 Aug;171(16):3777-800
pubmed: 24762001
Int Immunopharmacol. 2008 May;8(5):756-63
pubmed: 18387519
Front Pharmacol. 2020 Feb 28;11:83
pubmed: 32180715
Peptides. 2000 Jul;21(7):995-8
pubmed: 10998533
Chem Pharm Bull (Tokyo). 1989 Feb;37(2):425-9
pubmed: 2743487
J Drug Target. 2012 Feb;20(2):114-41
pubmed: 22023555
Am J Respir Cell Mol Biol. 2010 Feb;42(2):250-4
pubmed: 19448152
Life Sci. 2021 Jul 1;276:119428
pubmed: 33785346
Pediatr Allergy Immunol. 2021 Aug;32(6):1238-1254
pubmed: 33835532
Br J Pharmacol. 2016 Apr;173(8):1286-301
pubmed: 26756419
J Pharmacol Toxicol Methods. 1994 Apr;31(2):85-94
pubmed: 8032099
J Aerosol Med Pulm Drug Deliv. 2013 Oct;26(5):266-79
pubmed: 23273243
Bioengineered. 2021 Dec;12(1):8635-8649
pubmed: 34629023
J Aerosol Med Pulm Drug Deliv. 2019 Aug;32(4):224-241
pubmed: 30855199
Pharm Res. 2020 Sep 24;37(10):199
pubmed: 32968848
Arch Pediatr. 2020 Aug;27(6):315-321
pubmed: 32651143
Ther Deliv. 2016;7(4):257-78
pubmed: 27010987
Allergy Asthma Immunol Res. 2009 Oct;1(1):10-8
pubmed: 20224665
Curr Med Chem. 2015;22(13):1589-602
pubmed: 25666802
Open Life Sci. 2018 Oct 31;13:285-298
pubmed: 33817095
Biochem Med (Zagreb). 2011;21(3):203-9
pubmed: 22420233
Br J Pharmacol. 2014 Sep;171(17):4138-53
pubmed: 24903280